more

Abbott Laboratories (ABT)

(Real Time Quote from BATS)

$104.67 USD

-0.07 (-0.07%)

Updated May 13, 2024 03:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.20%
2	Buy	18.04%
3	Hold	9.52%
4	Sell	5.20%
5	Strong Sell	2.60%
S&P	500	11.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

Top 40% (100 out of 251)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Abbott's (ABT) i-STAT TBI Cartridge Receives FDA Approval

by Zacks Equity Research Published on April 02,2024

Abbott's (ABT) i-STAT Alinity instrument uses whole blood to help assess patients with a suspected mild traumatic brain injury or concussion.

Abbott (ABT) Declines More Than Market: Some Information for Investors

by Zacks Equity Research Published on April 01,2024

Abbott (ABT) concluded the recent trading session at $112.09, signifying a -1.38% move from its prior day's close.

ABTNegative Net Change

Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?

by Zacks Equity Research Published on April 01,2024

Sector ETF report for PJP

Abbott's (ABT) Assert-IQ Cardiac Monitor Receives CE Mark

by Zacks Equity Research Published on March 27,2024

Abbott's (ABT) Assert-IQ ICM enables regular monitoring for abnormal heart rhythms, as well as technologies to improve data management and workflow.

Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research Published on March 26,2024

In the closing of the recent trading day, Abbott (ABT) stood at $111.50, denoting a +1.35% change from the preceding trading day.

ABTNegative Net Change

Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It

by Zacks Equity Research Published on March 26,2024

Zacks.com users have recently been watching Abbott Laboratories (ABT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

ABTNegative Net Change

Abbott (ABT) Expands in Canada With First Eterna SCS Use

by Zacks Equity Research Published on March 25,2024

Abbott's (ABT) Eterna SCS system reduces pain without causing discomfort. It leverages the BurstDR stimulation technology.

medical

Apyx Medical (APYX) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research Published on March 21,2024

Apyx (APYX) delivered earnings and revenue surprises of -46.15% and 1.82%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Abbott (ABT) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research Published on March 20,2024

Abbott (ABT) closed at $111.50 in the latest trading session, marking a -1.47% move from the prior day.

ABTNegative Net Change

Abbott (ABT) Exceeds Market Returns: Some Facts to Consider

by Zacks Equity Research Published on March 19,2024

In the most recent trading session, Abbott (ABT) closed at $113.16, indicating a +0.64% shift from the previous trading day.

ABTNegative Net Change

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research Published on March 19,2024

Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research Published on March 19,2024

The average brokerage recommendation (ABR) for Abbott (ABT) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

ABTNegative Net Change

Abbott (ABT) is a Top-Ranked Momentum Stock: Should You Buy?

by Zacks Equity Research Published on March 18,2024

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ABTNegative Net Change

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

by Zacks Equity Research Published on March 15,2024

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

ABTNegative Net Change

Zacks Investment Ideas feature highlights: Tenet Healthcare and HCA Healthcare

by Zacks Equity Research Published on March 14,2024

Tenet Healthcare and HCA Healthcare are part of the Zacks Investment Ideas article.

etfs
medical

Medical Devices ETF Hits 52-Week High: Stocks to Watch

by Bryan Hayes Published on March 13,2024

Historically viewed as a defensive area, health care also boasts many growth aspects and benefits from advances in technology.

Roche (RHHBY) Launches AI-Based Predictive CGM Accu-Chek

by Zacks Equity Research Published on March 13,2024

Roche (RHHBY) is likely to enter the growing diabetes market with its AI-enabled predictive glucose monitoring system that may revolutionize diabetes management.

Abbott (ABT) Ascends But Remains Behind Market: Some Facts to Note

by Zacks Equity Research Published on March 12,2024

In the closing of the recent trading day, Abbott (ABT) stood at $120.76, denoting a +0.47% change from the preceding trading day.

ABTNegative Net Change

Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note

by Zacks Equity Research Published on March 11,2024

In the most recent trading session, Abbott (ABT) closed at $120.19, indicating a -0.64% shift from the previous trading day.

ABTNegative Net Change

Abbott (ABT) to Reduce Childhood Malnutrition With New Pact

by Zacks Equity Research Published on March 07,2024

Abbott's (ABT) latest partnership supports its sustainability goal of transforming care for malnutrition and improving the lives of 3 billion people per year by the decade's end.